Your browser doesn't support javascript.
loading
Expression of androgen receptors in primary breast cancer.
Park, S; Koo, J; Park, H S; Kim, J-H; Choi, S-Y; Lee, J H; Park, B-W; Lee, K S.
Afiliación
  • Park S; Department of Surgery.
  • Koo J; Department of Pathology.
  • Park HS; Department of Surgery.
  • Kim JH; Department of Surgery.
  • Choi SY; Department of Surgery.
  • Lee JH; Department of Surgery.
  • Park BW; Department of Surgery; Department of Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul. Electronic address: bwpark@yuhs.ac.
  • Lee KS; Department of Surgery, Pochon CHA University College of Medicine, Seongnam, Korea.
Ann Oncol ; 21(3): 488-492, 2010 Mar.
Article en En | MEDLINE | ID: mdl-19887463
BACKGROUND: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers. PATIENTS AND METHODS: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008 to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with >/=10% nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-square test. RESULTS: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer. However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human epidermal growth factor receptor type 2 (HER-2) overexpression. CONCLUSIONS: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores Androgénicos / Carcinoma Medular / Carcinoma Ductal de Mama / Carcinoma Intraductal no Infiltrante / Adenocarcinoma Mucinoso Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2010 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores Androgénicos / Carcinoma Medular / Carcinoma Ductal de Mama / Carcinoma Intraductal no Infiltrante / Adenocarcinoma Mucinoso Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2010 Tipo del documento: Article Pais de publicación: Reino Unido